http://www.trimeris.com/ http://www.synageva.com/ http://finance.yahoo.com/q/ks?s=GEVA http://finance.yahoo.com/q/ks?s=TRMS http://www.form4oracle.com/company?cik=0000911326&ticker=TRMS Trimeris, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutic agents for the treatment of viral disease in the United States and Canada. It provides a class of antiviral drug treatments, known as fusion inhibitors. Fusion inhibitors impair viral fusion, a process by which viruses attach to, penetrate, and infect host cells. The company offers FUZEON, is a 36-amino acid synthetic peptide that binds to a key region of an HIV surface protein called gp41. FUZEON blocks HIV viral fusion by interfering with certain structural rearrangements within gp41 that are required for HIV to fuse to and enter a host cell. It has a collaboration agreement with F. Hoffmann-La Roche, Ltd. to develop and market Fuzeon and T-1249, a replacement compound. The company was founded in 1993 and is based in Morrisville, North Carolina.